Citi sees Boston Scientific stopping TAVR valve sales as ‘wise move’

Citi analyst Joanne Wuensch keeps a Buy rating on Boston Scientific (BSX) with a $125 price target after the company announced the discontinuation of global Acurate neo2 and Acurate Prime transcatheter aortic valve replacement valve sales. The decision was made given “recent discussions with regulators, which resulted in increased clinical and regulatory requirements to maintain regulatory approvals in global markets and to obtain approvals in new regions.” Citi says Boston Scientific’s outside the U.S. TAVR revenue reached $214M in 2024, but the company has struggled to bring the product to the U.S., and outside the U.S. sales have weakened after unfavorable Acurate IDE clinical data. The firm views the discontinuation as a “wise move” when thinking about resource management. Boston Scientific still expects to reach Q2 and 2025 reported and organic sales and earnings guidance, Citi points out.